NICE
NICE Macular Oedema (Branch Retinal Vein Occlusion) Final Technology Appraisal
Response to NICE announcing their positive final guidance for Eylea® for the treatment of adult patients with visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO) The Royal College of Ophthalmologists welcomes the Final Appraisal Determination (FAD) from NICE recommending Eylea (aflibercept) as a first-line treatment option for patients with visual
NICE revision of Glaucoma Clinical Guidelines
NICE are in the process of revising Clinical Guideline CG85 ‘Glaucoma: Diagnosis and Management’, published in April 2009. The final scope of the proposed revision is available to read online via the NICE website. Key areas that will be covered in the revision include: The diagnostic accuracy of tests used for the provisional and definitive
Response to NICE guidance on Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Ciclosporin (1mg/ml, Ikervis®) is a sterile, positively charged, oil-in water, unpreserved ophthalmic emulsion for the treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes. It is administered as a once daily eye drop at bed time. The Royal College of Ophthalmologists welcomes the decision
French health regulator reviews use of Avastin to treat AMD
College Statement The RCOphth notes with interest the move by the French health regulator, French National Agency for Medicines and Health Products Safety (ANSM), in asking Roche to provide information on the safety and efficiency of the off-label use of bevacizumab (Avastin) to treat wet age-related macular degeneration (AMD). Ranibizumab (Lucentis), which is licensed as
NICE announce positive final guidance for Eylea® for the treatment of macular oedema secondary to CRVO
College Statement In response to NICE announcing their positive final guidance for Eylea® for the treatment of macular oedema secondary to CRVO The Royal College of Ophthalmologists welcomes the Final Appraisal Determination (FAD) from NICE recommending Eylea® (aflibercept) as a treatment option for visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).